top of page

Can We Please Stop Direct-to-Consumer Pharmaceutical Advertising?

The U.S. healthcare sector spends more money lobbying to advocate for policies that will benefit their members or businesses than any other sector, according to OpenSecrets. Last year, it spent $623 million on lobbying, for example; and in the first 6 months of 2021, spent nearly $331 million. PhRMA is coming at No. 1 this year, having spent over $15 million, while the American Medical Association is No. 4 for its $10.8 million January through June spend.

No wonder we're constantly being pummeled with direct-to-consumer drug advertising.

With so much being spent, who's looking out for the interests of orthopedic foot surgeons?

While the AOFAS is not a lobbying organization, it does support the efforts of other societies to advocate for foot and ankle orthopaedic surgeons and their patients. In July 2021, through an AAOS Sign-on letter, it gave support for the IPPS proposed rule on implementing performance measures based on outcomes.

And what about the interests of podiatric surgeons?

APMA is the only organization lobbying for podiatrists on Capitol Hill. Its Legislative Committee, Legislative Advocacy Department and Board of Trustees determine the issues and lobby Congress on behalf of the profession.

If it ain't broke, don't fix it

Minimally invasive surgery is here to stay, at least for the next decade. However, it will be interesting to see just how many of these techniques are truly adopted by surgeons – especially against mainstay open procedures that provide consistently reproducible outcomes.

7 views0 comments

Recent Posts

See All

Dr. Ned Amendola MD, FAAOS, FRCS(C) from Duke University was named second vice president of the American Academy of Orthopedic Surgeons (AAOS) and will ascend to president in 2025-2026. Fellowship tra

Startup capital is the fuel for innovation in foot and ankle surgery. There are several sources for capital with debt financing through banks representing one of them. Competition is good and the more

Chelsea spent close to $750 million on player acquisition in the past year, culminating in a $131 million deal for Enzo Fernández. The 21-year-old Argentine midfielder is now the most expensive player

FIX Masthead 2000x318 v2.jpg
bottom of page